Media headlines about Caladrius Biosciences (NASDAQ:CLBS) have been trending somewhat positive recently, Accern reports. The research firm identifies positive and negative media coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Caladrius Biosciences earned a media sentiment score of 0.03 on Accern’s scale. Accern also assigned news coverage about the biotechnology company an impact score of 44.6467935159371 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
Caladrius Biosciences (CLBS) traded up $0.15 on Friday, reaching $3.93. The company had a trading volume of 12,548 shares, compared to its average volume of 37,667. Caladrius Biosciences has a 1 year low of $2.63 and a 1 year high of $7.79.
A number of brokerages recently commented on CLBS. HC Wainwright set a $7.00 price objective on Caladrius Biosciences and gave the stock a “buy” rating in a research report on Friday, January 19th. Zacks Investment Research raised Caladrius Biosciences from a “hold” rating to a “buy” rating and set a $3.25 price objective for the company in a research note on Wednesday, November 15th.
Caladrius Biosciences Company Profile
Caladrius Biosciences, Inc is a cell therapy development company with product candidates in development based on multiple technology platforms and targeting autoimmune and cardiology indications. The Company’s lead product candidate, CLBS03, is a T regulatory cell (Treg) clinical Phase II therapy targeting adolescents with recent-onset type 1 diabetes mellitus (T1DM) using the patient’s own numerically and functionally enhanced Tregs.
Receive News & Ratings for Caladrius Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caladrius Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.